Short-course HSRT regimens yielded higher response and PFS rates at 6 months in patients with recurrent high-grade glioma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback